More big wins for the AstraZeneca-Daiichi Sankyo collaboration
Pharmaceutical Technology
AUGUST 16, 2022
Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.
Let's personalize your content